Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Change in Accured Expenses for 7 consecutive years, with -$4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 241.03% year-over-year to -$4.4 million, compared with a TTM value of -$10.1 million through Dec 2025, down 443.19%, and an annual FY2025 reading of -$10.1 million, down 443.19% over the prior year.
  • Change in Accured Expenses was -$4.4 million for Q4 2025 at Keros Therapeutics, up from -$4.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.7 million in Q3 2024 and bottomed at -$5.4 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $302600.0, with a median of $317500.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses skyrocketed 4494.85% in 2022, then plummeted 647.65% in 2023.
  • Year by year, Change in Accured Expenses stood at -$97000.0 in 2021, then surged by 4494.85% to $4.3 million in 2022, then skyrocketed by 35.75% to $5.8 million in 2023, then tumbled by 122.45% to -$1.3 million in 2024, then plummeted by 241.03% to -$4.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for KROS at -$4.4 million in Q4 2025, -$4.8 million in Q3 2025, and $2.7 million in Q2 2025.